Sinasprite: A Pilot Feasibility Study for Patients With Anxiety or Stress
Sinasprite: A Pilot Feasibility Study of a Casual Game for Primary Care Patients With Mild Stress, Anxiety or Depression
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Douglas M Maurer, DO, MPH
- Phone Number: 253-968-2911
- Email: douglas.m.maurer.mil@mail.mil
Study Locations
-
-
Washington
-
Tacoma, Washington, United States, 98401
- Madigan Army Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or older
- Eligible to receive care at a MHS clinic
- English-speaking
- In possession of a personal smartphone capable of downloading the Sinasprite application for use during the study
- Self-reported PHQ-9 score ≤ 10 and no self-reported suicidal or homicidal ideation
- Self-reported GAD-7 score ≤ 10 and no self-reported suicidal or homicidal ideation
- No change in antidepressant or antianxiety medication and/or dosage in past 3 months
Exclusion Criteria:
- Under 18 years of age
- English insufficient to interact with the game or complete assessments
- Residing in an institution or other living situation where health care decisions are not made by the participant (e.g., hospitalized, prisoners, people living in a rehabilitation facility)
- Self-reported PHQ-9 score > 10 or self-reported suicidal or homicidal ideation
- Self-reported GAD-7 score > 10 or self-reported suicidal or homicidal ideation
- Change in antidepressant or antianxiety medication and/or dosage in past 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sinasprite Mobile App
Mobile App
|
Mobile App
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient satisfaction. These data will be collected via questionnaire at the end of the study only
Time Frame: 12 wks
|
Data is via a standardized satisfaction questionnaire developed by the authors that is a mixture of open ended and likert scale questions on satisfaction with the app.
|
12 wks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measure of perceived stress (PSS)
Time Frame: Pre/post (0, 6 and 12 wks)
|
Participants will complete the 10 item perceived stress scale (PSS validated questionnaire) at 0, 6 and 12 wks.
|
Pre/post (0, 6 and 12 wks)
|
|
Quality of life (LiSAT-9)
Time Frame: Pre/post (0, 6 and 12 wks)
|
Participants will complete the LiSAT-9 validated questionnaire at 0, 6, and 12 weeks to assess their quality of life during the study.
|
Pre/post (0, 6 and 12 wks)
|
|
Symptom reports: measure of depression symptoms (PHQ-9 score)
Time Frame: Pre/post (0, 6, and 12 wks)
|
Participants will complete the 9 item PHQ-9 validated questionnaire at 0, 6, and 12 wks to assess participant symptoms of self-reported depression during the study.
|
Pre/post (0, 6, and 12 wks)
|
|
Symptom reports: measure of anxiety symptoms (GAD-7 score)
Time Frame: Pre/post (0, 6, and 12 wks)
|
Participants will complete the 7 item GAD-7 validated questionnaire at 0, 6, and 12 wks to assess participant symptoms of self-reported anxiety during the study.
|
Pre/post (0, 6, and 12 wks)
|
|
Measure of coping self-efficacy (CSE) questionnaire
Time Frame: Pre/post (0, 6 and 12 wks)
|
Participants will complete the 26 item coping self-efficacy (CSE) validated questionnaire at 0, 6 and 12 wks to assess their coping self-efficacy during the study.
|
Pre/post (0, 6 and 12 wks)
|
|
App daily usage (minutes/day)
Time Frame: 12 wks
|
Time (minutes per day) app was used
|
12 wks
|
|
App frequency usage (days/week)
Time Frame: 12 wks
|
Frequency (days/week) app was used
|
12 wks
|
|
App duration of usage (total weeks)
Time Frame: 12 wks
|
Weeks app was used
|
12 wks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 215019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.